Mersana Therapeutics, Inc.
840 Memorial Drive
About Mersana Therapeutics, Inc.
Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives.
Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug’s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Our management team has the experience, expertise and passion to translate the promise of our Fleximer platform into therapies that make a dramatic difference for patients. They bring to bear deep expertise in the critical disciplines of biology, chemistry, polymer science, drug development and oncology, and the collaborative leadership style needed to build a company of exceptional value.
CEO: Anna Protopapas
Chief Medical Officer: Dirk Huebner, M.D.
Chief Business Officer: Eva M. Jack
Chief Financial Officer: David A. Spellman
Chief Scientific Officer: Timothy B. Lowinger
68 articles with Mersana Therapeutics, Inc.
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
Synaffix Announces License Agreement with Mersana Therapeutics for the Use of its GlycoConnect™ Site-Specific ADC Technology
SynAffix B.V. announced it has entered into a license agreement with Mersana Therapeutics, Inc.
12/3/2018Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.
Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced it will present data on two new, novel antibody-drug conjugate (ADC) platforms at the AACR-NCI-EORTC International Conference
Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
Mersana Therapeutics, Inc (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that members of the senior management and scientific teams will present at the upcoming World ADC 2018 conference in San Diego, CA,
Shares of Cambridge, Mass.-based Mersana Therapeutics are up more than 7 percent in premarket trading after the company announced that it will be able to continue with its Phase I trial studying the antibody drug conjugate XMT-1522 as a potential treatment for some breast cancer patients.
7/19/2018Shares of Mersana Therapeutics have plunged nearly 40 percent this morning after the company announced the FDA placed a partial clinical hold on its Phase I antibody drug conjugate XMT-1522 following the death of a patient.
The Company will provide further details during its presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2018 at 4:00 pm PT.
Mersana’s addition to the NBI will become effective prior to market open on Monday, December 18th, 2017.
Mersana Announces First Patient Dosed With XMT-1536 in Phase I Study in Patients with NaPi2b-Expressing Tumors
Two expansion cohorts are expected to each enroll 30 patients with ovarian cancer and non-squamous non-small cell lung cancer.
Cash, cash equivalents and marketable securities as of September 30, 2017 were $133.4 million, compared with $100.3 million as of December 31, 2016.
Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference
Presentation highlights expanded pre-clinical data supporting the development of XMT-1536 in a broad population of patients with ovarian cancer.
Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b
This is the second IND clearance from Mersana’s novel dolaflexin ADC platform within the past year.
Mersana Adds To Antibody Drug Conjugate (ADC) Intellectual Property Portfolio With Issuance Of EP Patent